Coherus BioSciences (CHRS) Misses Q1 EPS by 205c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq futures drop over 1% as AI worries resurface, oil climbs
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.02 --0%
EPS Growth %: +39.4%
Financial Fact:
Gross profit: 261.73M
Today's EPS Names:
SICP, MNSB, CFFI, More
EPS Growth %: +39.4%
Financial Fact:
Gross profit: 261.73M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q1 EPS of ($0.35), $2.05 worse than the analyst estimate of $1.70. Revenue for the quarter came in at $7.6 million versus the consensus estimate of $54.36 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pool Corp. (POOL) Tops Q3 EPS by 4c; offers guidance
- Quest Diagnostics (DGX) Tops Q3 EPS by 13c; raises guidance
- Ardagh Metal Packaging S.A. (AMBP) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
